[1] LIPPI G, SANCHIS-GOMAR F, CERVELLIN G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge[J]. Int J Stroke, 2021, 16(2): 217. doi: 10.1177/1747493019897870
[2] LAM A, GOULOUTI E, ROTEN L. The search for atrial fibrillation and its impact on public health[J]. Swiss Med Wkly, 2017, 147: w14447.
[3] PROIETTI M. The dangerous combination of atrial fibrillation and hypertension: an urgent need to handle complexity[J]. Int J Cardiol, 2018, 254: 167. doi: 10.1016/j.ijcard.2017.12.036
[4] DILAVERIS P, ANTONIOU CK, MANOLAKOU P, et al. Biomarkers associated with atrial fibrosis and remodeling[J]. Curr Med Chem, 2019, 26(5): 780. doi: 10.2174/0929867324666170918122502
[5] LIU W, DENG J, DING W, et al. Decreased KCNE2 expression participates in the development of cardiac hypertrophy by regulation of calcineurin-NFAT and mitogen-activated protein kinase pathways[J]. Circ Heart Fail, 2017, 10(6): e003960. doi: 10.1161/CIRCHEARTFAILURE.117.003960
[6] CHEN L, JI Q, ZHU H, et al. miR-30a attenuates cardiac fibrosis in rats with myocardial infarction by inhibiting CTGF[J]. Exp Ther Med, 2018, 15(5): 4318.
[7] HE J, XU Y, YANG L, et al. Regulation of inward rectifier potassium current ionic channel remodeling by AT1-Calcineurin-NFAT signaling pathway in stretch-induced hypertrophic atrial myocytes[J]. Cell Biol Int, 2018, 42(9): 1149. doi: 10.1002/cbin.10983
[8] WU G, WANG Z, SHAN P, et al. Suppression of Netrin-1 attenuates angiotension Ⅱ-induced cardiac remodeling through the PKC/MAPK signaling pathway[J]. Biomed Pharmacother, 2020, 130: 1.
[9] 李梦. 益母草碱抗心肌纤维化的作用及机制研究[D]. 贵阳: 贵阳中医学院, 2017.
[10] HINDRICKS G, POTPARA T, DAGRES N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the Euro-Pean Association for Cardio-Thoracic Surgery[J]. Eur Heart J, 2021, 42(5): 373.
[11] DOTAN N, GAYDER V, BLOCH I, et al. An ELISA for the study of calcineurin-NFAT unstructured region interaction[J]. Anal Biochem, 2018, 549: 66. doi: 10.1016/j.ab.2018.03.014
[12] STAERK L, SHERER JA, KO D, et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes[J]. Circ Res, 2017, 120(9): 1501. doi: 10.1161/CIRCRESAHA.117.309732
[13] OIKONOMOU E, ZOGRAFOS T, PAPAMIKROULIS GA, et al. Biomarkers in atrial fibrillation and heart failure[J]. Curr Med Chem, 2019, 26(5): 873. doi: 10.2174/0929867324666170830100424
[14] GUPTA DK, SHAH AM, GIUGLIANO RP, et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48[J]. Eur Heart J, 2014, 35(22): 1457. doi: 10.1093/eurheartj/eht500
[15] LIU CF, ZHOU WN, GUO TM, et al. Liver Enzymes and the risk of atrial fibrillation: a meta-analysis of prospective cohort studies[J]. Genet Test Mol Biomarkers, 2019, 23(12): 865. doi: 10.1089/gtmb.2019.0142
[16] ALONSO A, MISIALEK JR, AMⅡN MA, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the atherosclerosis risk in communities cohort[J]. Heart, 2014, 100(19): 1511. doi: 10.1136/heartjnl-2014-305756
[17] HARADA M, NATTEL S. Implications of inflammation and fibrosis in atrial fibrillation pathophysiology[J]. Card Electrophysiol Clin, 2021, 13(1): 25. doi: 10.1016/j.ccep.2020.11.002
[18] HOGAN PG. Calcium-NFAT transcriptional signalling in T cell activation and T cell exhaustion[J]. Cell Calcium, 2017, 63: 66. doi: 10.1016/j.ceca.2017.01.014
[19] LIN CC, LIN JL, LIN CS, et al. Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation[J]. Chest, 2004, 126(6): 1926. doi: 10.1016/S0012-3692(15)31443-4
[20] ZHAO Y, CUI GM, ZHOU NN, et al. Calpain-calcineurin-nuclear factor signaling and the development of atrial fibrillation in patients with valvular heart disease and diabetes[J]. J Diabetes Res, 2016, (4): 639.
[21] XIAO L, GU Y, GAO L, et al. Sanggenon C protects against pressure overloadinduced cardiac hypertrophy via the calcineurin/NFAT2 pathway[J]. Mol Med Rep, 2017, 16(4): 5338. doi: 10.3892/mmr.2017.7288
[22] ROSIN NL, FALKENHAM A, SOPEL MJ, et al. Regulation and role of connective tissue growth factor in AngⅡ-induced myocardial fibrosis[J]. Am J Pathol, 2013, 182(3): 714. doi: 10.1016/j.ajpath.2012.11.014
[23] HONG L, LAI HL, FANG Y, et al. Silencing CTGF/CCN2 inactivates the MAPK signaling pathway to alleviate myocardial fibrosis and left ventricular hypertrophy in rats with dilated cardiomyopathy[J]. J Cell Biochem, 2018, 119(11): 9519. doi: 10.1002/jcb.27268
[24] LI Y, JIAN Z, YANG ZY, et al. Increased expression of connective tissue growth factor and transforming growth factor-beta-1 in atrial myocardium of patients with chronic atrial fibrillation[J]. Cardiology, 2013, 124(4): 233. doi: 10.1159/000347126